Adjuvant therapy for pancreatic cancer

Area of Science:

• Oncology
• Surgical Oncology
• Gastroenterology

Background:

• Pancreatic cancer is a leading cause of cancer mortality with limited survival improvements.
• Radical surgery alone does not guarantee a cure for pancreatic cancer.
• Adjuvant therapy shows potential for resectable pancreatic tumors.

Purpose of the Study:

• To review current and emerging therapeutic strategies for pancreatic cancer.
• To evaluate the role of adjuvant and neoadjuvant therapies in improving patient outcomes.
• To highlight the need for definitive randomized trials and novel agent assessment.

Main Methods:

• Review of conventional chemotherapy and radiotherapy, including 5-fluorouracil and external beam radiation therapy (EBRT).
• Assessment of neoadjuvant therapy to increase resection suitability.
• Evaluation of regional therapy techniques for localized treatment.
• Analysis of retrospective nonrandomized series and ongoing randomized trials.

Main Results:

• Conventional adjuvant therapies (chemotherapy, EBRT) have shown some survival benefits.
• Neoadjuvant and regional therapies aim to enhance treatment potential and resectability.
• Existing data primarily comes from retrospective studies, limiting definitive conclusions.
• Novel agents are under investigation for advanced pancreatic cancer treatment.

Conclusions:

• Adjuvant therapy plays a role in managing resectable pancreatic cancer.
• Further randomized trials are crucial to establish the efficacy of conventional adjuvant therapy.
• Novel therapeutic approaches are essential for improving outcomes in advanced pancreatic cancer.